Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL28542970 | 0.89 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7524766 | 0.89 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL23539449 | 0.88 | — | — | |
| SCHEMBL1758688 | 0.86 | GRIN2D (0.62) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL602384 | 0.84 | GAA (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24728057 | 0.84 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL26521449 | 0.84 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7091493 | 0.83 | GRIN2D (0.42) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9240799 | 0.82 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11697939 | 0.82 | GRIN2D (0.68) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 706 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751879-A | Adamantane modified silane coupling agent, single-component dealcoholized silicone rubber and preparation method thereof | 广州白云科技股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-118546393-A | Self-adaptive self-healing hydrogel and preparation method and application thereof | 思味趣生物科技(上海)有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-108285439-B | Carbonoside sodium glucose transport protein body 2 inhibitor | 江苏天士力帝益药业有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-7235342-B2 | Negative photoresist composition including non-crosslinking chemistry | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2007-06-26 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-20050164507-A1 | Negative photoresist composition including non-crosslinking chemistry | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2005-07-28 | — | — | US | claimed |
| CN-122070936-A | Nanometer material based on supermolecule polypeptide-drug coupling prodrug, and preparation method and application thereof | 中国医学科学院生物医学工程研究所 | 2026-05-22 | — | — | CN | disclosed |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-4332086-B1 | COMPOUND OR SALT THEREOF, LIPID PARTICLES, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORP (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| US-12540148-B2 | Lipophosphonoxins, their preparation and use | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2026-02-03 | — | — | US | disclosed |
| CN-121450214-A | High-performance formula of pencil wax sealing primer and preparation method thereof | 浙江安益新材料有限公司 | 2026-02-03 | — | — | CN | disclosed |
| EP-4658663-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-1985004168-A1 | SOFT beta-ADRENERGIC BLOCKING AGENTS | BODOR NICHOLAS S | 1985-09-26 | — | — | WO | disclosed |
| US-4525475-A | Prevention of thrombolic disorder with imidazole derivatives and salts thereof | THOROGOOD PETER B (GB) | 1985-06-25 | — | — | US | disclosed |
| EP-0015002-B1 | 1-SUBSTITUTED IMIDAZOLES, AND SALTS THEREOF, A METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS THEREOF | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-04-18 | — | — | EP | disclosed |
| EP-0053621-A1 | UNSATURATED ESTERS OF ADAMANTANE CONTAINING DIOLS AND THERMO-RESISTANT CROSS-LINKED POLYMERS THEREFROM. | BATTELLE MEMORIAL INSTITUTE (CH) | 1982-06-16 | — | — | EP | disclosed |
| US-4328234-A | Imidazole derivatives and salts thereof and pharmaceutical formulations useful in thrombo-embolic disorders | BURROUGHS WELLCOME CO. (US) | 1982-05-04 | — | — | US | disclosed |
| WO-1981003657-A1 | UNSATURATED ESTERS OF ADAMANTANE CONTAINING DIOLS AND THERMO-RESISTANT CROSS-LINKED POLYMERS THEREFROM | BATTELLE MEMORIAL INSTITUTE (CH) | 1981-12-24 | — | — | WO | disclosed |
| EP-0015002-A1 | 1-substituted imidazoles, and salts thereof, a method for their preparation and pharmaceutical formulations thereof | THE WELLCOME FOUNDATION LIMITED (GB) | 1980-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | GRIN2D 3455/4885GRIN3B 2909/4885GRIN1 2574/4885 |
| US-12540148-B2 | Lipophosphonoxins, their preparation and use | PLD1, LYPLA1, LPAR3 | GRIN2D 3019/4885GRIN3B 3036/4885GRIN1 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.